BusinessAbeona Therapeutics Announces Upcoming Conference ParticipationBy Nasdaq OMXFeb 21, 2018, 1:45 PM UTC
BusinessAbeona Reports Third Quarter 2017 Financial Results and Recent Business HighlightsBy Nasdaq OMXNov 15, 2017, 1:25 PM UTC
BusinessAbeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene TherapiesBy Nasdaq OMXOct 16, 2017, 12:26 PM UTC
BusinessAbeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIABy Nasdaq OMXOct 11, 2017, 12:19 PM UTC
BusinessAbeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the MesaBy Nasdaq OMXOct 6, 2017, 12:25 PM UTC
BusinessAbeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102By Nasdaq OMXSep 28, 2017, 12:32 PM UTC
BusinessAbeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis BullosaBy Nasdaq OMXAug 29, 2017, 1:05 PM UTC
BusinessAbeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017By Nasdaq OMXAug 17, 2017, 1:15 PM UTC
